Graft-vs-host disease after small bowel transplantation in children. 2010

Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
Department of Pediatric Surgery, Hospital Universitario La Paz, Paseo de Castellana 261, 28046 Madrid, Spain. aneandresmo@hotmail.com

OBJECTIVE Graft-vs-host disease (GVHD) is a rare complication of transplantation of organs rich in immunocompetent cells. The goal of this study was to report the features of GVHD after small bowel transplantation (SBTx) in children. METHODS The study involved a retrospective review of patients undergoing SBTx between 1999 and 2009 who had GVHD. RESULTS Of 46 children receiving 52 intestinal grafts (2 liver-intestine and 3 multivisceral), 5 (10%) developed GVHD. Median age at transplant was 42 (19-204) months. Baseline immunosupression consisted of tacrolimus and steroids supplemented with thymoglobulin (n = 2) or basiliximab (n = 3) for induction. Median time between transplantation and GVHD was 47 (16-333) days. All patients had generalized rash, 2 had diarrhea, and 2 had respiratory symptoms. Other symptoms were glomerulonephritis (n = 1) and conjunctivitis (n = 1). Four developed severe hematologic disorders. The diagnosis was confirmed by skin biopsy in 4 patients and supported by chimerism studies in two. Colonoscopy and opthalmoscopic findings were also suggestive in one. Treatment consisted of steroids and decrease of tacrolimus, with partial response in four. Other immunosuppressants were used in refractory or recurrent cases. Three patients died within 4 months after diagnosis. CONCLUSIONS Graft-vs-host disease is a devastating complication of SBTx, with high mortality probably associated with severe immunologic dysregulation.

UI MeSH Term Description Entries
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007223 Infant A child between 1 and 23 months of age. Infants
D007421 Intestine, Small The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM. Small Intestine,Intestines, Small,Small Intestines
D008297 Male Males
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal

Related Publications

Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
June 1992, Transplantation proceedings,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
February 1989, Transplantation proceedings,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
December 1990, Transplantation proceedings,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
September 1991, The British journal of surgery,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
October 1996, Transplantation proceedings,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
August 1992, Transplantation proceedings,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
January 1990, Hepatology (Baltimore, Md.),
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
August 1992, Transplantation proceedings,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
September 1995, Digestive diseases and sciences,
Ane M Andres, and Manuel Lopez Santamaría, and Esther Ramos, and Jesus Sarriá, and Manuel Molina, and Francisco Hernandez, and Jose L Encinas, and Javier Larrauri, and Gerardo Prieto, and Juan Antonio Tovar
August 1990, Scandinavian journal of immunology,
Copied contents to your clipboard!